Idera Pharmaceuticals to Present at the Piper Jaffray Healthcare Conference

CAMBRIDGE, Mass., Dec. 2, 2014 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. IDRA, a clinical-stage biopharmaceutical company developing novel nucleic acid therapeutics for cancer and rare diseases, today announced that Company management will present at the 26^th Annual Piper Jaffray Healthcare Conference on Wednesday, December 3, 2014 at 3:30 p.m. EST in New York.

A live audio webcast of the presentation will be available in the Investors and Media section of Idera's website at http://www.iderapharma.com or at the link http://www.media-server.com/m/p/kkrv2ds7. An archived version will also be available on the Company's website after the event for 90 days.

About Idera Pharmaceuticals

Idera Pharmaceuticals is a clinical-stage biopharmaceutical company developing a novel therapeutic approach for the treatment of genetically defined forms of B-cell lymphoma and rare autoimmune diseases. Idera's proprietary technology involves creating novel nucleic acid therapeutics designed to inhibit over-activation of Toll-like Receptors (TLRs). In addition to its TLR programs, Idera is developing gene silencing oligonucleotides (GSOs) that it has created using its proprietary technology to inhibit the production of disease-associated proteins by targeting RNA. To learn more about Idera, visit www.iderapharma.com.